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Abstract 39 
Sexually transmitted Chlamydia trachomatis causes infertility, and because almost 90% of 40 
infections are asymptomatic, a vaccine is required for its eradication. Mathematical modeling 41 
studies have indicated that a vaccine eliciting partial protection (non-sterilizing) may prevent 42 
Chlamydia infection transmission, if administered to both sexes prior to an infection. 43 
However, reducing chlamydial inoculum transmitted by males and increasing infection 44 
resistance in females through vaccination to elicit sterilizing immunity has yet to be 45 
investigated experimentally. Here we show that a partially protective vaccine (chlamydial 46 
major outer membrane protein – MOMP and ISCOMATRIX – IMX) provided sterilizing 47 
immunity against sexual transmission between immunized mice. Immunizing male or female 48 
mice prior to an infection reduced chlamydial burden and disease development, but did not 49 
prevent infection. However, infection and inflammatory disease responsible for infertility 50 
were absent in 100% of immunized female mice challenged intravaginally with ejaculate 51 
collected from infected immunized males. In contrast to the sterilizing immunity generated 52 
following recovery from a previous chlamydial infection, protective immunity conferred by 53 
MOMP/IMX occurred independent of resident-memory T cells. Our results demonstrate that 54 
vaccination of males or females can further protect the opposing sex, whereas vaccination of 55 
both sexes can synergize to elicit sterilizing immunity against Chlamydia sexual 56 
transmission.  57 
 58 
 59 
 60 
 61 
 62 
 63 
 64 
 65 
 66 
 67 
 68 
 69 
 70 
 71 
 72 
Introduction 73 
In Australia, C. trachomatis accounts for 81% of all notifiable sexually transmitted infections 74 
and cases have increased from 14,045 in 1999 to 74,305 in 2010 (1). Women are 2 to 3 times 75 
more likely than men to contract an infection (2) and also have a higher incidence of 76 
asymptomatic infection, 70 – 90% compared to 40 – 60% in men (3). As the financial burden 77 
of Chlamydia infection is determined by the ease and cost of diagnosis, treatment and 78 
management of associated diseases (e.g. infertility), women account for 80% of the total 79 
economic cost of Chlamydia infections (4). Consequently, developing a vaccine that protects 80 
females from infection and disease has been the primary focus, despite studies showing the 81 
benefits of targeting both sexes (5). 82 
We are reliant on animals to model infection transmission, and chlamydial research is most 83 
commonly conducted using the murine model, in which female mice require progesterone 84 
pretreatment to enhance their susceptibility to infection (6). Unfortunately, female mice 85 
become less receptive to mating during progesterone-induced diestrus (7), which prevents the 86 
study of sexual transmission between infected males and infection-susceptible female mice. 87 
Researchers instead utilize direct intravaginal inoculation of progesterone-primed female 88 
mice with Chlamydia to model sexual transmission. However, the infective dose can be 89 
highly variable between research groups, which can influence the kinetics of infection, 90 
immunity and disease development (8, 9). The inoculums of Chlamydia often used to infect 91 
mice are also considerably higher than the amount identified in guinea pigs and humans to be 92 
passed naturally through sexual transmission (10-12). Direct intravaginal inoculation of 93 
female mice with Chlamydia in sucrose buffer also cannot replicate the effects male ejaculate 94 
has on female genital tract immunity (13). Therefore, there is a need to improve the current 95 
model of Chlamydia sexual transmission in mice to test intervention strategies like vaccines.  96 
The chlamydial major outer membrane protein (MOMP) is the most commonly used antigen 97 
in chlamydial vaccine research (14). However, the superior quality of MOMP-specific 98 
immunity that develops following a natural infection with Chlamydia, as opposed to simple 99 
immunization with MOMP, suggests that current adjuvant technology is failing to fully 100 
exploit the protective capabilities of MOMP. Similar in structure to ISCOMs (15), 101 
ISCOMATRIX® (IMX) is simply mixed with the antigen but does not need to encapsulate it 102 
to have an adjuvant effect, as the addition of phosphatidyl (choline or ethanol amine) into 103 
IMX during manufacturing provides exposed functional groups that allows for antigen 104 
conjugation through non-covalent interactions. IMX is safe and well-tolerated in humans and 105 
shown to elicit long-lived T and B cell responses in clinical trials (15). As protection against 106 
a chlamydial genital tract infection is dependent on effective antigen presentation by dendritic 107 
cells and the induction of both T and B cells (16), the combination of MOMP and IMX 108 
together with intranasal (IN) administration to elicit a mucosal response could formulate an 109 
effective vaccine against a genital tract infection. 110 
By challenging infection-susceptible (progesterone-primed) female mice with ejaculates 111 
collected from infected males we could simulate Chlamydia sexual transmission in mice. 112 
Immunization with MOMP/IMX elicited partial protection against infection in both males 113 
and females; however, infection and disease were completely absent from immunized female 114 
mice challenged with infectious prostatic fluid collected from immunized males, indicating a 115 
synergism between the partial immunity in both sexes.  116 
Results 117 
MOMP-specific T and B cell responses generated following immunization 118 
A MOMP-specific cell-mediated and humoral immune response contributes significantly 119 
towards protection against a Chlamydia genital tract infection (17). We therefore isolated 120 
splenocytes from immunized mice and quantified the expansion and cytokine production of 121 
their T helper cells (Th)  (CD3+CD4+) and cytotoxic T cells (Tc) (CD3+CD8+) 122 
(Supplementary Figure 1) cells following in vitro re-stimulation with MOMP. Th, but not Tc 123 
cells isolated from MOMP/IMX immunized animals showed a significantly higher level of 124 
proliferation following re-stimulation with MOMP (p<0.001) when compared to the 125 
unimmunized control (Fig. 1A). MOMP-specific Th cells isolated from MOMP/IMX 126 
immunized mice also showed significant staining for IFNγ (p<0.001), TNFα (p<0.001), IL-127 
17 (p<0.001) when compared to unimmunized controls (Fig. 1B). Similarly, Tc cells 128 
displayed significant staining for IFNγ (p<0.05) and IL-17 (p<0.001) when compared to 129 
unimmunized controls. Further analysis of the MOMP-specific Th cells isolated from the 130 
MOMP/IMX immunized animals indicated that approximately 60% were multifunctional 131 
(IFNγ+TNFα+IL-17+, TNFα+IL-17+ IFNγ+IL-17+, p<0.001) compared to <10% in the 132 
unimmunized control groups (Fig: 1C). Tc cells in MOMP/IMX immunized mice were 133 
primarily of the single-positive phenotype (IFNγ+, IL-17+ or TNFα+) and not significantly 134 
different from the unimmunized control. Immune responses generated following 135 
immunization were identical in male and female mice (data not shown). 136 
Immunization with MOMP/IMX generated MOMP-specific sera and vaginal IgG and IgA 137 
(Fig 1D) and these were significantly greater than those detected following an intravaginal 138 
infection (LIC, p<0.01). Sera from MOMP/IMX immunized mice significantly neutralized 139 
Chlamydia infectivity in vitro when compared to naïve sera (p<0.05) (Fig. 1E). Stimulation 140 
of RAW264.7 with Chlamydia opsonized with sera from MOMP/IMX immunized also 141 
promoted expression of CXCL1 (7-fold), CXCL2 (1.5-fold) and IL-1β (2-fold) mRNA (Fig 142 
1F) after 24 hrs of stimulation.  143 
Determining the infectious dose of Chlamydia transmitted by male mice 144 
The bacterial burden in the prostatic fluid, prostate and testes remained constant from week 1 145 
to week 10 post-infection (p.i) (Fig. 2A and B). The bacterial burden in the penis peaked at 146 
week 10 p.i, although this had little effect on the total amount of viable Chlamydia collected 147 
in the prostatic fluid over the course of the infection. Males produced 4.7 ± 1.7 µL (BALB/c) 148 
and 4.4 ± 2.4 µL (C57BL/6) of prostatic fluid (data not shown). The chlamydial load in the 149 
prostatic fluids contained 49 ± 20 IFU (BALB/c) and 64 ± 35 IFU (C57BL/6) of Chlamydia. 150 
Infected males were mated with receptive females (non-progesterone primed) at weeks 1 and 151 
2 p.i and the transmissible chlamydial load in their ejaculate was determined indirectly from 152 
the females (Fig. 2C and D). Samples collected from female mice that were mated with males 153 
at week 1 p.i contained the most Chlamydia IFU. Vaginal lavages collected from mated 154 
BALB/c females contained 251 ± 27 IFU (♂BALB/c) and 258 ± 34 IFU (♂C57BL/6), whilst 155 
the vaginal plugs contained 225 ± 153 IFU (♂BALB/c) and 165 ± 50 IFU (♂C57BL/6) of 156 
Chlamydia. For both direct and indirect sample collection methods, the transmissible dose 157 
was determined to be 18 – 503 IFU/ejaculate (Supplementary Figure 2).  158 
Protection against infection and disease in female mice following challenge with sexually 159 
transmissible doses of Chlamydia 160 
Vaginal shedding was significantly reduced in MOMP/IMX immunized animals challenged 161 
with 5x101 IFU on day 3 (15-fold) (p<0.001) and 6 p.i (5-fold) (p<0.001) when compared to 162 
the unimmunized control group (Fig. 3A). All unimmunized control animals challenged with 163 
5x101 IFU of C. muridarum developed a cultivatable vaginal infection, whereas, 20% of 164 
immunized animals remained culture negative from the point of challenge up until days 12 – 165 
15 days post-challenge. This suppressive effect on infection in the vagina was abrogated 166 
when immunized animals were challenged with doses of 1x102 IFU or greater. However, the 167 
duration of infection and chlamydial shedding was still significantly reduced in the vagina of 168 
MOMP/IMX immunized animals when compared to the unimmunized control groups on day 169 
6 p.i (3-fold) when mice were challenged with 1x102 IFU (p<0.001) (Fig. 3B), as well as on 170 
day 3 (4-fold) (p<0.001) when mice were challenged with 5x102 IFU (Fig. 3C). Immunized 171 
mice began clearing the infection in the lower genital tract from day 9 – 15 p.i, compared to 172 
day 21 – 35 p.i for the unimmunized group. Immunization elicited a significant level of 173 
protection against the severity of oviduct pathology following challenge with 5x101 (p<0.001) 174 
(Fig. 3A), 1x102 (p<0.001) (Fig. 3B) and 5x102 (p<0.01) (Fig. 3C), when compared to 175 
unimmunized controls. Mice recovered from a previous intravaginal chlamydial infection 176 
elicit sterilizing immunity against re-challenge. A prior infection (live infection control –  177 
LIC) elicited sterilizing immunity against all challenge doses, but no protection against the 178 
development of oviduct pathology. 179 
Immune response in the genital tract of female mice following challenge with sexually 180 
transmissible doses of Chlamydia 181 
By isolating cells from the entire genital tract (sans ovaries) (Fig. 4), we could identify 182 
differences in immune cell recruitment between immunized (MOMP/IMX), unimmunized 183 
(PBS) and immune mice (LIC) and link each cell infiltrate profile with its respective 184 
infection/disease protection profile. Leukocytes (CD45+) (Fig. 4A), neutrophils (CD45+Gr-185 
1+) (Fig. 4B), macrophages (CD45+F4/80+) (Fig. 4C), B cells (CD45+CD19+) (Fig. 4D) Th 186 
cells (CD45+CD3+CD4+) (Fig. 4E) and Tc cells (CD45+CD3+CD8) (Fig. 4F) were analyzed 187 
(Supplementary Figure 3). Recruitment of B, Th and Tc cells into the genital tracts occurred 188 
on day 8 following challenge in both immunized and unimmunized animals. Although 189 
numbers of B, Th and Tc cells recruited to the genital tract were consistently greater in 190 
immunized versus unimmunized mice, levels were not significantly different between groups. 191 
Tc cells were however present in significant numbers in the genital tract of the LIC group 192 
prior to re-challenge (day 0) (p<0.001) and on days 2 and 4 p.i (p<0.05) when compared to 193 
the unimmunized controls. Th cell numbers were also significantly increased in the female 194 
genital tracts of mice in the LIC when compared to unimmunized mice on days 2 and 4 195 
(p<0.05) following challenge, indicating a rapid recruitment of Th cells in the LIC group. 196 
Neutrophil and macrophage numbers were not significantly different between immunized and 197 
unimmunized mice. Uterine horn tissue sections were also stained for neutrophils (Gr-1+) 198 
(Fig. 4G), macrophages (F4/80+) (Fig. 4H), B cells (B220+) (Fig. 4I) and T cells (CD3+) 199 
(Fig. 4J), which matched those determined by flow cytometry. Interestingly, 8 – 15% of Tc 200 
cells isolated from the genital tract of mice from the LIC on day 2 p.i were also CD103+, 201 
indicating they were tissue resident memory T cells (TRM) (18) (Fig. 5). However, TRM 202 
(CD3+CD8+CD103+) diminished to background levels within one week of the secondary 203 
challenge. 204 
Gene expression of immune cells sorted from the genital tract of female mice following 205 
challenge with a sexually transmissible dose of Chlamydia 206 
As no significant differences in the anamnestic response were observed in the genital tract 207 
between immunized and unimmunized female mice, we assessed gene expression in whole 208 
oviduct tissues (Fig. 6A) and leukocytes recruited into the genital tract, sorted 209 
(Supplementary Figure 3) into macrophages (Fig. 6B), neutrophils (Fig. 6C), Tc cells (Fig. 210 
6D) and Th cells (Fig. 6E) to identify functional differences. Th and Tc cells isolated on day 211 
8 p.i from MOMP/IMX immunized mice expressed significantly more IFNγ (8- and 6-fold, 212 
respectively), TNFα (2- and 6-fold, respectively) and IL-17A (10- and 12-fold, respectively) 213 
than unimmunized mice. Similarly, Th and Tc cells isolated on day 2 p.i from LIC mice 214 
expressed significantly more IFNγ (6- and 2-fold, respectively), TNFα (2- and 3-fold, 215 
respectively) and IL-17A (3- and 13-fold, respectively) than unimmunized mice on day 8 p.i. 216 
Neutrophils and macrophages isolated on day 8 p.i from MOMP/IMX immunized mice 217 
expressed significantly more CXCL1 (2-fold) and IL-1β (2- and 4-fold, respectively) than 218 
unimmunized mice. Similar increases in gene expression were also detected in the whole 219 
oviduct gene expression. This pattern of cytokine and chemokine expression in the oviduct of 220 
MOMP/IMX immunized mice on day 2 p.i was similar to the gene expression RAW264.7 221 
cell line stimulated with opsonized C. muridarum (Fig 1F).  222 
In vivo depletion and passive immunization 223 
To confirm the roles of T and B cells in protection in female mice, we depleted Th (CD4+), 224 
Tc (CD8β+) and B cells (CD20+) following immunization but prior to challenge. Th, Tc and 225 
B cells (Supplementary Figure 4) were successfully depleted from the spleen and the genital 226 
tract following administration of αCD4, αCD8 and αCD20, respectively. MOMP-specific Ig 227 
was not reduced in the serum or vaginal lavages of MOMP/IMX immunized mice following 228 
B cell depletion (Supplementary Figure 4). Naïve mice were also passively immunized with 229 
sera collected from MOMP/IMX immunized mice. Serum antibody levels were found to be 230 
comparable between passively immunized and MOMP/IMX immunized mice 231 
(Supplementary Figure 4). Depletion of CD4+ and CD8+ but not CD20+ cells from 232 
MOMP/IMX immunized mice prior to challenge, inhibited protection against infection and 233 
oviduct pathology (Fig. 7A). Depletion of CD4+ but not CD8+ or CD20+ cells from 234 
unimmunized mice prior to challenge inhibited the natural resolution of the infection, but did 235 
not exacerbate oviduct pathology (Fig. 7B). Depletion of CD8+ and CD4+ but not CD20+ 236 
cells prior to re-challenge mitigated sterilizing immunity in LIC mice, but did not exacerbate 237 
oviduct pathology (Fig. 7C). Passive immunization of naïve mice with serum from 238 
MOMP/IMX reduced vaginal shedding between days 3 and 6 p.i when compared to infusion 239 
of sera collected from unimmunized mice, but did not affect oviduct pathology (Fig. 7D).  240 
Protection against Chlamydia infection transmission between male and female mice 241 
Immunization conferred partial protection against infection in female mice, although it is 242 
unclear if vaccinating males prior to their infection could prevent or reduce the risk of 243 
infection transmission to immunized female mice. Unimmunized female mice challenged 244 
with the prostatic fluid collected from unimmunized males (week 1 p.i) developed a 245 
comparable vaginal infection and disease to females challenged with known doses of 5x101, 246 
1x102 and 5x102 IFU of C. muridarum (Fig. 8A). Immunization of male mice prior to 247 
challenge significantly reduced the amount of Chlamydia detectable in the penis and testes, 248 
but not in prostatic fluid (Supplementary Figure 5). However, unimmunized female mice 249 
challenged with the infectious prostatic fluids from immunized males exhibited no reduction 250 
in infection or disease when compared to infection with unimmunized male ejaculates (Fig. 251 
8B). Half of immunized female mice showed sterilizing immunity against challenge with the 252 
infectious prostatic fluid from unimmunized males (p<0.001), but these mice showed no 253 
protection from disease when compared to challenge of unimmunized females (Fig. 8C). 254 
Interestingly, no immunized female mice challenged with the infectious ejaculate of 255 
immunized males acquired an infection or developed any oviduct pathology (p<0.001) (Fig. 256 
8D), indicating complete protection against Chlamydia sexual transmission between 257 
immunized males and females. 258 
Discussion 259 
The ability of an animal model to replicate sexual transmission of infection is crucial for the 260 
development of a human vaccine against Chlamydia. To date, only large and/or expensive 261 
animal models (non-human primates, pigs and guinea pigs) have been shown to transmit a 262 
chlamydial infection sexually (16). In this study, we determined the transmissible infectious 263 
dose in the ejaculate of male mice (18 to 503 IFU) in order to develop a mouse model of 264 
sexual transmission. This dose range determined for mice is comparable with Guinea pigs 265 
that transmit approximately 100 IFU of C. caviae (11, 12). Semen from C. trachomatis-266 
infected human males has also been shown to contain between 675 – 1.6x104 copies/mL of 267 
chlamydial DNA (10). With an average ejaculate volume of 4.66 mL (10), a transmissible 268 
infectious dose for humans would range between 3146 – 7.5 x104 copies/ejaculate, which 269 
closely matches the amount contained in mouse prostatic fluid (2080 – 1.16x105 270 
copies/prostatic fluid). Therefore, we suggest that an inoculum of C. muridarum between 50 271 
and 500 IFU should be used for all future vaccine studies as this dose is not only capable of 272 
establishing an infection in all test animals, but it also reflects a physiologically relevant 273 
inoculum that could be passed naturally during sexual transmission. 274 
Surprisingly, 20% of immunized female mice initially resisted the establishment of a genital 275 
tract infection for 12 – 15 days post-challenge with the sexually transmissible dose of 50 IFU. 276 
Despite the expansion of MOMP-specific and multifunctional Th and Tc cells following 277 
immunization, these could not be detected in the genital tract until day 8 p.i. Conversely, 278 
significant levels of MOMP-specific antibodies were generated following immunization, 279 
which were also shown to neutralize Chlamydia infectivity in vitro and reduce vaginal 280 
shedding on days 3 and 6 p.i following infusion into naïve animals. In support of finding by 281 
others (19), this indicates that induction of humoral immunity through immunization is 282 
crucial for neutralizing the initial challenge inoculum, an important effect that was masked 283 
when using higher, non-physiological challenge doses of C. muridarum (>5x103 IFU) (data 284 
not shown).  285 
Expression of chemokines (CXCL1, CXCL2 and CXCL5) and cytokines (IFNγ, TNFα and 286 
IL-1β) were up-regulated in the oviducts of immunized compared to unimmunized mice. 287 
Macrophages and neutrophils isolated from the genital tracts of immunized mice also showed 288 
a similar up-regulated pattern of cytokine and chemokine expression as the oviducts, 289 
indicating an increased level of activation, antimicrobial and chemotactic activity (16). This 290 
occurred during the early stages of the infection (day 2 p.i) where the presence of MOMP-291 
specific antibodies in the genital tract of immunized animals was the only observed 292 
difference from unimmunized mice. Opsonization and complement are known to promote 293 
chemokines and cytokine production by APCs (20) and we too found that Chlamydia 294 
incubated with sera containing MOMP-specific antibodies enhanced expression of cytokines 295 
and chemokines by monocyte/macrophages in vitro. This indicated that in addition to their 296 
neutralizing effects, antibodies generated following immunization might also contribute 297 
towards protection by enhancing innate and adaptive responses through the induction of 298 
cytokines and chemokines. 299 
The recruitment of T cells into the genital tract on day 8 p.i coincided with the resolution of 300 
the infection in immunized animals. However, unimmunized mice failed to resolve an 301 
infection from day 8 p.i despite mounting a T cell response comparable in both speed and 302 
magnitude to immunized animals. This indicated that functional differences existed between 303 
T cells recruited in immunized and unimmunized animals. Immunization induced expansion 304 
of MOMP-specific splenic Th and Tc cells, which produced IFNγ, TNFα and IL-17A upon in 305 
vitro re-stimulation. Th and Tc cell isolated from the genital tracts of immunized mice on day 306 
8 p.i were also found to express more IFNγ, TNFα and IL-17A than T cells isolated from 307 
unimmunized animals. These cytokines have been consistently shown to contribute to 308 
protection against infection and disease (21). Protection against vaginal shedding was 309 
alleviated following depletion of CD4+ and CD8+ cells, indicating an important role for Th 310 
and Tc cells in protection elicited by MOMP/IMX.   311 
Animals recovered from a previous infection with Chlamydia (LIC group) demonstrated 312 
sterilizing immunity against re-challenge; therefore, it is important to compare the 313 
mechanisms of protection between MOMP/IMX immunized and LIC mice as this can 314 
highlight potential inadequacies in vaccine design. T cells were not detectable in the genital 315 
tract of MOMP/IMX immunized until day 8 p.i, whereas Tc cells were present in the genital 316 
tract of LIC mice prior to re-challenge and Th cells were rapidly recruited by day 2 p.i. Some 317 
Tc cells present in the genital tract of LIC mice prior to challenge were CD103+ and 318 
localized in the epidermis, which is consistent with the phenotype of TRM in female genital 319 
tract of mice during a HSV-2 infection (22). However, TRM we not detected in the genital 320 
tract of MOMP/IMX immunized mice even following challenge (day 2 – 8 p.i.). Tc cells 321 
isolated from the genital tracts of mice in the LIC group immediately prior to re-challenge 322 
(day 2 p.i) expressed increased levels of cytokines, which were associated with the rapid 323 
recruitment of Th cells. This is also consistent with existing literature regarding the 324 
functionality of TRM, that they provide a means of “sense and alarm” (23) by secreting 325 
cytokines and chemokines, which recruit effector Th cells necessary to eradicate the 326 
infection. Th and Tc cells recruited in the genital tract of MOMP/IMX immunized mice 327 
exhibited a similar pattern of increased cytokine expression as T cells from LIC, but were 328 
recruited later at day 8 p.i. Reduction of Tc cells numbers, including the TRM, in the genital 329 
tract of LIC mice prior to re-challenge abrogated sterilizing immunity, which indicated that 330 
Tc cells are capable of preventing infection from sexually transmissible doses of Chlamydia. 331 
Th cells were also shown to contribute to sterilizing immunity in LIC mice, however; it is 332 
unclear if Th cells had a direct effect or if their depletion during the resolution of the primary 333 
infection inhibited the development of TRM (24). Further phenotypic characterization, 334 
functionality and longevity studies will also be required to definitively characterize TRM, 335 
although this to our knowledge is the first indication that a small number of TRM may be 336 
generated following a chlamydial infection. Comparison between immunized and LIC mice 337 
indicate that strategies to accelerate T cell recruitment into the genital tract, like the “prime-338 
pull” approach (25), must be implemented if future vaccines are to achieve immunity 339 
equivalent to that which develops following a natural infection. 340 
Mathematical modeling has been invaluable in determining the attributes a vaccine must 341 
possess in order to impact on infection transmission (5, 26). Assertions that non-sterilizing 342 
vaccines, if targeted towards both sexes, could interrupt infection transmission had not yet 343 
been investigated experimentally (5). Challenging female mice with prostatic fluids collected 344 
from infected males to model sexual transmission (Fig. 9A), we determined that the 345 
immunization status (immunized or unimmunized) of both sexes was critical for the induction 346 
of sterilizing immunity against infection and disease. Immunizing females was more effective 347 
against preventing infection transmission than immunizing males (Fig. 9B and C), as reported 348 
elsewhere (5). This could be attributed to the inherent difficulties in resolving an infection in 349 
the immune-privileged male genital tract and the vaccine eliciting a potent cell-mediated 350 
response as opposed to the more male protective humoral response (27). However, male 351 
vaccination status protected against the development of oviduct pathology in immunized 352 
females (Fig. 9D). As this reduction in severity and incidence of disease was not detected in 353 
unimmunized females, it is likely to be independent of bacterial burden. Instead, additional 354 
adaptive immune components like antibodies, chemokines or cytokines present in the 355 
ejaculate of immunized males may have provided cross talk with immunity in immunized 356 
females (13, 28). This indicates that anti-chlamydial immunity against infection will be 357 
dependent on a vaccine for females, whereas a vaccine targeting males may be required for 358 
protection against diseases associated with infertility.  359 
In this study, analysis of the local immune response in the genital tract following a 360 
Chlamydia infection provides the first evidence that TRM confer/are essential for sterilizing 361 
immunity against challenge and should be the target of future vaccines. Induction of TRM in 362 
females may be required to elicit complete protection against an infection transmitted from an 363 
unimmunized male. A partially protective vaccine targeting females would have a greater 364 
impact on Chlamydia infection and disease than a male vaccine; however, sterilizing 365 
immunity, i.e. prevention of sexual transmission, would require vaccination of both sexes. It 366 
has been consistently shown in the most at risk adolescent age group that sexual behavior and 367 
perception of risk to other sexually transmitted infections is unaltered by vaccination (29); 368 
therefore, the introduction of a non-sterilizing Chlamydia vaccine together with existing 369 
surveillance and antibiotic treatment programs could facilitate a decline in infection rates.  370 
Materials and Methods 371 
Ethics statement 372 
Animal care and use protocols in this study adhered to the National Health and Medical 373 
Research Council guidelines to promote the wellbeing of animals used for scientific 374 
purposes. This study was approved by the Queensland University of Technology Animal 375 
Ethics Committee (QUT UAEC No. 1100000588 and 1400000010) and carried out in strict 376 
accordance with any recommendations. All animals were euthanized humanely by 377 
intraperitoneal injection with sodium pentobarbital (200 mg/kg). 378 
Animals and Chlamydia 379 
Mice (C57BL/6 and BALB/c) were sourced from the Animal Resource Centre (ARC, 380 
Canningvale, Australia) at 6 weeks of age. Animals were given food and water ad libitum. C. 381 
muridarum (Weiss strain), was a generous gift from Catherine O’Connell and cultured from 382 
McCoy cells and purified as previously described (30).  383 
Immunization 384 
Recombinant C. muridarum MOMP-MBP was purified and IN immunizations were 385 
performed as previously described (31). The vaccine contained recombinant MOMP (50 µg) 386 
and ISCOMATRIX® (10 µg) (Zoetis, Florham Park, USA) mixed in a 10 µL volume, 5 µL 387 
applied to each nare. Animals were immunized once on four separate occasions (days 0, 7, 14 388 
and 28).  389 
Antibodies and flow cytometry 390 
Cells were washed with 2%v/v fetal calf serum (FCS)/phosphate-buffered saline (PBS) 391 
before blocking with αCD16/CD32 – FcγR (Clone: 24G2) for 15 min at 4°C. Cells were 392 
labeled with Zombie Green Viability Dye (Cat No. 423112, Biolegend, San Diego, USA) 393 
prior to staining with αCD3 (Clone: 145-2C11, Cat No 100330 – Biolegend, San Diego, 394 
USA), αCD4 (Clone: RM4.5, Cat No. 562314 – BD Bioscience, San Jose, USA), αCD8α 395 
(Clone: 53.6-7, Cat No. 25-0081 – eBioscience, San Diego, USA), αCD19 (Clone: 1D3, Cat 396 
No. 551001 – BD Bioscience), αCD45 (Clone: 30-F11, Cat No. 562129 – BD Bioscience), 397 
αCD103 (Clone: 2E7, Cat No. 121408 – Biolegend), αGr-1 – Ly6C/Ly6G (Clone: RB6-8C5, 398 
Cat No. 108412 – Biolegend) and αF4/80 (Clone: BM8, Cat No. 123110 – Biolegend) in a 399 
volume of 50 µL for 15 min at 4°C. Cells were washed with 2% FCS/PBS before fixing using 400 
4%w/v paraformaldehyde for 10 min at 4°C. Fixed cells were permeabilized for intracellular 401 
cytokine staining using Perm/Wash (Cat No. 554723 – BD Bioscience) according to the 402 
manufacturer’s instructions. Permeabilized cells were stained with αIFNγ (Clone: XMG1.2, 403 
Cat No. 554413 – BD Bioscience), αTNFα (Clone: MP6-XT22, Cat No. 554418 – BD 404 
Bioscience) and αIL-17 (Clone: TC11-18H10, Cat No. 559502 – BD Bioscience) diluted in 405 
Perm/Wash buffer for 40 min at 4°C. Stained cells were analyzed on the FACSAria III (BD 406 
Bioscience) using Flowjo version X software (Tree Star Inc, Ashland, USA). 407 
In vivo depletion and passive immunization 408 
Depletion of CD4+ (Clone: GK1.5, IgG2b, 1 x 200 µg), CD8β+ (Clone: 53-5.8 (32), IgG1, 1 409 
x 250 µg IP, 2 x 50 µg intravaginally) (BioXcell, West Lebanon, USA) and CD20+ cells 410 
(Clone: 5D2, IgG2a, 1 x 250 µg) (Genentech Inc, San Francisco, USA) was performed 411 
following IP injection of each monoclonal antibody on day 13 prior to intravaginal challenge. 412 
Identical doses of αTNP (Clone: 2A3, IgG2a), αHRP (Clone: HRPN, IgG1) or αKLH (Clone: 413 
LTF-2, IgG2b) (BioXcell) were used as isotype controls. Passive immunization of naïve mice 414 
was performed one day prior to intravaginal challenge by IP infusion of 500 µL of serum 415 
collected from MOMP/IMX or PBS immunized mice. 416 
Sample collection and tissue processing 417 
Vaginal lavages and serum were collected as previously described (21). Spleens processed as 418 
described previously (21) and cultured in complete Dulbecco’s minimal essential medium 419 
(DMEM) (5%v/v fetal calf serum (FCS), 4 mM L-glutamine, 50 µg/mL gentamicin, 100 420 
µg/mL streptomycin sulfate) (Invitrogen, Carlsbad, USA) containing 50 µM β-421 
mercaptoethanol. Genital tract tissues were digested in complete DMEM containing 500 422 
U/mL of collagenase I and 120 µg/mL DNase I (Invitrogen) for 1 hr shaking at 37°C.  423 
MOMP-specific T cell proliferation and cytokine production  424 
Cells were stained with carboxyfluorescein succinimidyl ester (CFSE) (Sigma-Aldrich, St. 425 
Louis, USA) (5 µM) for 5 min at room temperature. Labeled splenocytes were stimulated 426 
with media containing recombinant MOMP (10 µg/well) for 96 hrs at 37°C with 5% CO2. 427 
Cells were incubated for an additional 12 hrs in complete DMEM containing brefeldin A 428 
(Sigma-Aldrich) (10 µg/mL) before intracellular cytokine staining. 429 
MOMP-specific antibody quantification, in vitro neutralization of Chlamydia infectivity 430 
and opsonization 431 
Antigen-specific antibodies were measured by enzyme-linked immunosorbent assay (ELISA) 432 
and in vitro C. muridarum neutralization assay were performed as previously described (21).  433 
Monocytes/macrophage cell line RAW264.7 (ATCC TIB–71) were grown in RPMI 1640, 434 
HEPES, 10%v/ FCS, 4 mM L-glutamine, 50 µg/mL gentamicin, 100 µg/mL streptomycin. C. 435 
muridarum was incubated with a 1/20 dilution of serum for 1 hr at 37°C with 5% CO2, then 436 
added to RAW264.7 cells at an MOI of 1 and incubated for 2, 4, 6 and 24 hrs.  437 
Intrapenile and intravaginal infections  438 
Intrapenile challenges were performed on mice by exposing the glans and inoculating the 439 
exterior of the urethra with 1x106 IFU of C. muridarum in 5 µL of sucrose-phosphate-440 
glutamine (SPG) (219 mM sucrose, 3.8 mM KH2PO4, 8.6 mM Na2HPO4, 4.9 mM glutamic 441 
acid, pH 7.35).  442 
Female mice received 2.5 mg of medroxyprogesterone (DepoProvera) subcutaneously, seven 443 
days prior to challenge with C. muridarum. Mice anaesthetized with ketamine (Parnell 444 
Laboratory, Alexandria, Australia) (100 mg/Kg) /xylazine (Bayer, Leverkusen, Germany) (10 445 
mg/Kg) were challenged intravaginally with C. muridarum in 20 µL of SPG two weeks 446 
following immunization. Mice recovering from a primary infection of 5x101, 1x102 or 5x102 447 
IFU (6 weeks) were also re-challenged with the same dose as the primary infection to act as a 448 
live infection control (LIC) group.  449 
Prostatic fluid collection, mating and sexual transmission 450 
Male mice were maintained under isoflurane-induced anesthesia and placed on their backs for 451 
collecting prostatic fluid. Urine was drained from the bladder using a syringe prior to 452 
collection. Ejaculation was induced following electro-stimulation of the prostate using a 453 
custom made probe and the square wave generator (Universal Kymograph – Harvard 454 
Apparatus, Massachusetts, USA) (Supplementary Figure 6). The prostatic fluid was collected 455 
into a capillary tube and expelled into a tube before making the volume up to 20 µL with cold 456 
SPG.  457 
Infected males were mated with non-progesterone primed females during the peak of their 458 
infection (day 7 – 14 post-infection – p.i) at the beginning of the 12 hr dark cycle. Paired 459 
mice were observed for 1 hr and vaginal lavages were collected following the first instances 460 
in which a female mated with a male for ≥10 sec. Paired mice were then left for the 461 
remaining dark cycle and inspected for vaginal plugs at the beginning of the following 12 hr 462 
light cycle. Vaginal plugs were excised and homogenized in 800 µL of SPG using the OMNI 463 
TH tissue homogenizer. The uterine horns were flushed with 200 µL of the same SPG 464 
containing the vaginal plug.   465 
Quantification of C. muridarum from secretions, tissues and swabs 466 
Infected tissues (≤250 mg) were excised and homogenized in 800 µL of SPG. Vaginal swabs 467 
were collected using a sterile nasopharyngeal swab (Copan, Murrieta, USA) and stored in 468 
500 µL of SPG containing two glass beads. The SPG supernatant was used to quantify 469 
chlamydial content by culture as previously described (21). Ejaculate was also screened by 470 
culture and ompA-specific qRT-PCR as described previously (31).  471 
RNA extraction and RT-PCR 472 
Genital tract tissues were equilibrated in RNAlater (QIAGEN, Venlo, Netherlands) then total 473 
RNA was extract using the RNeasy Tissue Mini Kit (Cat. No. 74704) and treated with 474 
RNase-free DNase (QIAGEN). RNA was extracted immediately from sorted cells using 475 
Trizol (Invitrogen) and 10 µg of glycogen carrier protein (Cat No. AM9510, Applied 476 
Biosystems, Foster City, USA) according to manufacturer’s instructions. cDNA was 477 
synthesized using High Capacity Reverse Transcriptase Kit (Applied Biosystems) (Cat. No. 478 
4368814) as per the manufacturer’s instructions. Each reaction contained 10 ng of cDNA, 1 479 
µM of forward/reverse primers (Supplementary Figure 7) (Sigma-Aldrich), 200 µM dNTP’s, 480 
1.5 mM MgCl2, 1X buffer, 0.15X SYBR green, and 5 U of Platinum Taq polymerase 481 
(Invitrogen) made up to a final 20µL volume using sterile endonuclease-free water. RT-PCR 482 
was performed using the Corbet Rotorgene Q (QIAGEN). Gene expression was analyzed 483 
using Hierarchical Clustering Explorer 3.5 Analysis Tool (University of Maryland, USA). 484 
Immunohistochemistry 485 
Immunohistochemistry was performed by the HistoTechnology Facility (Queensland Institute 486 
of Medical Research, Brisbane, Australia) as described previously (21).  487 
Gross oviduct pathology 488 
The oviduct diameter was measured on day 35 p.i to assess the severity of pathology (33, 34). 489 
The incidence of oviduct pathology (presence or absence) was the number of mice presenting 490 
with hydrosalpinx (unilateral and bilateral). 491 
Power calculations and statistical analysis 492 
Sample sizes were determined a priori using a one-tailed, Proportions: Inequality, two 493 
independent groups Fischer’s exact test in G*Power 3.1.7 software (Institute for 494 
Experimental Psychology, Dusseldorf, Germany). Statistical analysis of graphical data was 495 
performed using GraphPad Prism® version 5.00 (GraphPad, La Jolla, USA).  496 
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 614 
 615 
Figure 1: MOMP-specific T and B cell responses following immunization  616 
Cells were isolated from spleens of immunized (MOMP/IMX) or nonimmunized (PBS) mice 617 
(7 day post-immunization) or infected mice (intravaginally challenged with 5x104 IFU of C. 618 
muridarum, 21 day p.i), stimulated with MOMP for 5 days and analyzed by flow cytometry 619 
for antigen-specific proliferation and cytokine production. Live cells (viability stain) were 620 
gated initially on single cells (FSC-A/FSC-H) and lymphocytes (FSC/SSC) before gating 621 
CD3+ cells on Th (CD3+CD4+) and Tc cells (CD3+CD8+). (A) Cells were labeled with 622 
CFSE and stimulated with MOMP to measure the percentages of MOMP-specific Th and Tc 623 
cell proliferation (n = 10). (B) MOMP-specific Th cells staining positive for IFNγ, TNFα and 624 
IL-17 are represented as a percentage of total Th cells (n = 10). (C) MOMP-specific Th cells 625 
staining positive for TNFα were assessed for multifunctional phenotype (IFNγ and IL-17) are 626 
represented as a percentage of total cytokine producing Th cells (n = 10). (D) MOMP-627 
specific IgG, IgA, IgG2a and IgG1 endpoint titers were quantified in serum and vaginal 628 
lavage (VL) samples by ELISA. (E) In vitro neutralization of Chlamydia infectivity was 629 
determined for serum and vaginal lavage by culture (n = 10). (F) The ability of serum 630 
collected from MOMP/IMX immunized mice to opsonize Chlamydia and promote CXCL1, 631 
CXCL2 and IL-1β production by monocytes/macrophages (RAW264.7 cell line) was 632 
determined using RT-PCR. Results are presented as the mean ± SEM. ND refers to “not 633 
done”. Significant differences were determined using a one-way ANOVA with Tukey’s post-634 
test. Significance was set at p<0.05 for all tests. p>0.05 (not shown), 0.01-0.05 (*), 0.001-635 
0.01 (**) and <0.001 (***). 636 
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 643 
 644 
 645 
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 647 
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 649 
Figure 2: Quantification of the chlamydial dose sexually transmitted by male mice.  650 
(A) Male BALB/c and (B) C57BL/6 mice were challenged with 1x106 IFU C. muridarum 651 
and the chlamydial burden was quantified from the prostatic fluid, penis, prostate and testes 652 
collected on week 1, 2, 5 and 10 p.i by culture (n = 5). (C) Male mice were challenged (Ch) 653 
with C. muridarum and mated (M) with non-progesterone primed females (receptive) and the 654 
chlamydial load transmitted was determined from vaginal lavages (VL) (n = 11) and (D) 655 
vaginal plugs (VP) (n = 15) during weeks 1 and 2 of their infection. Results are presented, as 656 
the mean ± SEM. Significant differences were determined using a one-way ANOVA with 657 
Tukey’s post-test. Significance was set at p < 0.05 for all tests. p>0.05 (not shown), 0.01-0.05 658 
(*), 0.001- 0.01 (**) and <0.001 (***). 659 
 660 
 661 
Figure 3: Protection against genital tract infection and oviduct pathology in female mice 662 
following immunization and challenge with sexually transmissible doses of C. 663 
muridarum.  664 
Female BALB/c mice were immunized (MOMP/IMX), nonimmunized (PBS) or infected (1° 665 
infection, intravaginally challenged with 5x101, 1x102 and 5x102 IFU of C. muridarum) then 666 
challenged with (A) 5x101, (B) 1x102, (C) 5x102 IFU of C. muridarum. Vaginal swabs were 667 
collected over 28 days p.i to quantify the amount of Chlamydia shed (IFU/mL) by culture. 668 
Significant levels of bacterial burden were determined using a two -way ANOVA with 669 
Tukey’s post -test. Results are presented as the mean ± SEM. Percentages of mice shedding 670 
Chlamydia from the vagina on the days following challenge are also presented. Significant 671 
differences were determined using a Kaplan -Meier survival curve and the log rank post -test. 672 
The severity of pathology was determined by measuring the diameter of the oviducts post-673 
mortem on day 35 p.i. The solid line across the graph represents the mean width of unaffected 674 
oviducts (2 mm). Significance of disease severity was determined using a one -way ANOVA 675 
with Tukey’s post -test. Significance was set at p < 0.05 for all tests. p>0.05 (not shown), 676 
0.01-0.05 (*), 0.001- 0.01 (**) and <0.001 (***). 677 
 678 
 679 
 680 
 681 
Figure 4: Kinetics of leukocyte, neutrophil, macrophage, B, Th and Tc cell recruitment 682 
following immunization and challenge with a sexually transmissible dose of C. 683 
muridarum.  684 
Female BALB/c mice were immunized (MOMP/IMX), nonimmunized (PBS) or infected (1° 685 
infection, intravaginally challenged with 5x101 IFU of C. muridarum) then challenged with 686 
5x101 IFU of C. muridarum. Tissues were collected from immunized mice (MOMP/IMX and 687 
PBS) prior to challenge (day 0) and on days 2, 4 and 8 following challenge (n = 6). Tissues 688 
were also collected from uninfected animals (no infection control – NIC) on days 2, 4 and 8 689 
and mice recovering from an intravaginal infection (day 0 = 1° infection, day 21 p.i) and on 690 
days 2, 4 and 8 p.i following re-challenge (live infection control – LIC) (n = 6). Cells were 691 
isolated from the uterine horns and cervix/vagina by digestion for analysis by flow cytometry. 692 
Live cells (viability stain) were gated initially on single cells (FSC-A/FSC-H) and (A) 693 
leukocytes (CD45+) before gating on (B) neutrophils (Gr-1+), (C) macrophages (F4/80+), 694 
(D) B cells (CD19+), (E) Th cells (CD3+CD4+) and (F) Tc cells (CD3+CD8+). Results are 695 
presented as number of cells per 2x104 events. Uterine horns were also fixed for analysis by 696 
immunohistochemistry (n = 6). Serial tissue sections of the uterine horns were stained for the 697 
presence of (G) neutrophils (Gr-1+), (H) macrophages (F4/80+), (I) B cells (B220+), (J) and 698 
T cells (CD3+). Representative images (4x and 20x magnifications) are shown for each stain. 699 
ImageScope software was used to quantify the percentage positivity (positive pixels/total 700 
pixels) from a high-resolution image of each section. Results are presented as the mean ± 701 
SEM. Significant differences were determined using a one-way ANOVA with Tukey’s post-702 
test. Significance was set at p < 0.05 for all tests. p>0.05 (not shown), 0.01-0.05 (*), 0.001- 703 
0.01 (**) and <0.001 (***). 704 
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 720 
Figure 5: Kinetics of TRM cells (CD3+CD8+CD103+) following immunization and 721 
challenge with a sexually transmissible dose of C. muridarum.  722 
Female BALB/c mice were immunized (MOMP/IMX), nonimmunized (PBS) or infected (1° 723 
infection, intravaginally challenged with 5x101 IFU of C. muridarum) then challenged with 724 
5x101 IFU of C. muridarum. Tissues were collected from immunized mice (MOMP/IMX and 725 
PBS) prior to challenge (day 0) and on days 2, 4 and 8 following challenge (n = 3). Tissues 726 
were also collected from uninfected animals (no infection control – NIC) and mice 727 
recovering from an intravaginal infection (day 0 = 1° infection, day 21 p.i) and on days 2, 4 728 
and 8 p.i following re-challenge (live infection control – LIC) (n = 3). Cells were isolated 729 
from the uterine horns and cervix/vagina by digestion for analysis by flow cytometry. (A) 730 
Resident memory Tc were identified by gating on lymphocytes (FSC/SSC), single cells (FSC 731 
-A/FSC -H), leukocytes (CD45+), Tc cells (CD3+CD8+) and finally CD103+. (B) Cells per 732 
2x104 events are presented for each group. Results are presented as the mean ± SEM. (C) 733 
CD3 staining of tissue sections from uterine horns collected from LIC and NIC groups prior 734 
to challenge. Significant differences were determined using a one -way ANOVA with 735 
Tukey’s post -test. Significance was set at p < 0.05 for all tests. p>0.05 (not shown), 0.01-736 
0.05 (*), 0.001- 0.01 (**) and <0.001 (***). 737 
 738 
 739 
Figure 6: Gene expression in whole oviducts, macrophages, neutrophils, Tc and Th cells 740 
isolated from the oviducts following immunization and challenge with a sexually 741 
transmissible dose of C. muridarum.  742 
Female BALB/c mice were immunized (MOMP/IMX), nonimmunized (PBS) or infected (1° 743 
infection, intravaginally challenged with 5x101 IFU of C. muridarum) then challenged with 744 
5x101 IFU of C. muridarum. Tissues were collected from immunized mice (MOMP/IMX and 745 
PBS) prior to challenge (day 0) and on days 2, 4 and 8 following challenge. Tissues were also 746 
collected from uninfected animals (no infection control – NIC) and mice recovering from an 747 
intravaginal infection (day 0 = 1° infection, day 21 p.i) and on days 2, 4 and 8 p.i following 748 
re-challenge (live infection control – LIC) (n = 3). (A) Gene expression was performed on 749 
pooled oviducts (n = 3) and fold change (scale 0 – 100-fold) was calculated relative to the 750 
uninfected control (NIC). Live cells were isolated from the genital tract on days 2 and 8 p.i 751 
and separated into (B) macrophages (CD45+F4/80+) (C) neutrophils (CD45+Gr-1+), (D) Tc 752 
(CD45+CD3+CD8+) and (E) Th cells (CD45+CD3+CD4+) using flow cytometry (n = 10). 753 
Cytospin and Geimsa staining was performed on sorted cell fractions to compare surface 754 
marker phenotype with nuclear morphology (representative image shown). Gene expression 755 
was performed on pooled cells isolated from the oviducts, uterine horns and cervix vagina (n 756 
= 10), and fold changes (scale 0 – 10-fold) were calculated relative to an unimmunized 757 
control. Significant differences were determined using a one-way ANOVA with Tukey’s 758 
post-test. Significance was set at p < 0.05 for all tests. p>0.05 (not shown), 0.01-0.05 (*), 759 
0.001- 0.01 (**) and <0.001 (***). 760 
 761 
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Figure 7: In vivo depletion (CD4+, CD8+ and CD20+) and passive immunization prior 777 
to challenge with a sexually transmissible dose of C. muridarum.  778 
Female BALB/c mice were immunized (MOMP/IMX), nonimmunized (PBS) or infected (1° 779 
infection, intravaginally challenged with 5x104 IFU of C. muridarum) and depleted of CD4, 780 
CD8 and CD20 cells (n = 5). Unimmunized mice were also passively immunized with serum 781 
collected from MOMP/IMX immunized mice (n = 5). Depleted and passively immunized 782 
mice were then challenged with 5x101 IFU of C. muridarum. Vaginal infection and oviduct 783 
pathology were quantified from (A) MOMP/IMX, (B) unimmunized, (C) LIC and (D) 784 
passively immunized naïve mice. Vaginal swabs were collected for 28 days p.i to quantify the 785 
amount of Chlamydia shed (IFU/mL) by culture. The severity of pathology was determined 786 
on day 35 p.i by measuring the diameter of the oviducts. The solid line across the graph 787 
represents the mean width of unaffected oviducts (2 mm). Results are presented as the mean 788 
± SEM. Significant levels of bacterial burden and disease severity were determined using a 789 
one-way ANOVA with Tukey’s post-test. Significance was set at p < 0.05 for all tests. 790 
p>0.05 (not shown), 0.01-0.05 (*), 0.001- 0.01 (**) and <0.001 (***). 791 
 792 
793 
Figure 8: Transmission of Chlamydia between male and female mice with different 794 
vaccination statuses.  795 
(A) Male mice were challenged (Ch) with 1x106 IFU C. muridarum and their prostatic fluids 796 
(PF) were collected 7 days p.i (n = 10). Female mice were progesterone-primed (P) 7 days 797 
prior to being challenged intravaginally with prostatic fluid collected from the infected males 798 
(n = 5). Vaginal shedding and development of hydrosalpinx following challenge with PF was 799 
compared to challenge of female mice with 5x101, 1x102 and 5x102 of C. muridarum. This 800 
model of sexual transmission was repeated using (B) males, (C) females and (D) males and 801 
females that had been immunized (IM) with MOMP/IMX (M/I) prior to challenge with PF (n 802 
= 10). Vaginal swabs (VS) were collected over 28 days p.i to quantify the amount of 803 
Chlamydia shed (IFU/mL) by culture. Significant levels of bacterial burden were determined 804 
using a two-way ANOVA with Tukey’s post-test. Results are presented as the mean ± SEM. 805 
Percentages of mice shedding Chlamydia from the vagina on the days following challenge 806 
are also presented. Significant differences were determined using a Kaplan -Meier survival 807 
curve and the log rank post-test. Protection against the severity of oviduct pathology 808 
(hydrosalpinx) in female mice challenge with prostatic fluid was determined post mortem (†) 809 
on day 35 p.i by measuring oviduct diameter. The solid line across the graph represents the 810 
mean width of unaffected oviducts (2 mm). Results are presented as the mean ± SEM. 811 
Significant levels of bacterial burden and disease severity were determined using a one -way 812 
ANOVA with Tukey’s post -test. Significance was set at p < 0.05 for all tests. p>0.05 (not 813 
shown), 0.01-0.05 (*), 0.001- 0.01 (**) and <0.001 (***). 814 
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Figure 9:  Prevention of Chlamydia sexual transmission by vaccination. 835 
(A) Chlamydia infection transmission occurs unimpeded though unimmunized mice. (B) Risk of 836 
infection transmission to unimmunized females is unaffected by the male vaccination status. (C) 837 
Vaccinating female mice reduces their risk of acquiring an infection from unimmunized males by 838 
50%, but not their risk of developing disease. As half of immunized females were protected from 839 
an infection, risk of infection transmission and disease developing in unimmunized males is also 840 
reduced. (D) No transmission of infection occurs between immunized males and females. 841 
Immunized females show no signs of disease. Further transmission to unimmunized males is also 842 
prevented. 843 
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S1: Chlamydia quantified from infectious male mouse ejaculate 851 
Sample Prostatic fluid Vaginal lavage Vaginal plug 
Min – Max 
(IFU) 18 – 224 135 – 449 72 – 503 
Mean ± SD 
(IFU) 68 ± 45 261 ± 98 220 ± 150 
Min – Max 
(ompA copies) 2080 – 1.2x10
5 ND 1.7x105 – 3x107 
Mean ± SD 
(ompA copies) 3x10
4 ± 6657 ND 5x106 ± 8.5x106 
Minimum, maximum and mean amount of Chlamydia collected from prostatic fluid, vaginal 852 
lavage and vaginal plugs determined by culture (IFU) and RT-PCR (ompA copies). Results 853 
are a combination of both strains (BALB/c and C57BL/6) and time points (W1 and W2). ND 854 
abbreviation refers to “not done”. 855 
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S2: Gating strategies for MOMP-specific T cell responses following immunization  866 
(A) Live cells (viability stain) were gated initially on single cells (FSC-A/FSC-H) and 867 
lymphocytes (FSC/SSC) before gating CD3+ cells on Th (CD3+CD4+) and Tc cells 868 
(CD3+CD8+). (B) Cells were labeled with CFSE and stimulated with MOMP to measure the 869 
percentages of MOMP-specific Th and Tc cell proliferation. (C) MOMP-specific Th cells 870 
staining for IFNγ, TNFα and IL-17. (D) MOMP-specific Th cells staining positive for TNFα 871 
were assessed for multifunctional phenotype (IFNγ and IL-17) and represented as a 872 
percentage of total cytokine producing Th cells.  873 
 874 
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 876 
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S3: Gating strategies for macrophages, neutrophils, Tc and Th cells isolation and purity 878 
Live cells were isolated from the genital tract on days 2 and 8 p.i and separated into (A) 879 
macrophages (CD45+F4/80+) and neutrophils (CD45+Gr-1+), (B) Tc (CD45+CD3+CD8+) 880 
and Th cells (CD45+CD3+CD4+) using flow cytometry. Representative plots for 881 
macrophages (92.8%) and neutrophils (99.7%), Tc (93.8%) and Th cells (98%) purity are 882 
shown. 883 
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S4: Confirmation of in vivo depletion (CD4+, CD8+ and CD20+) and passive 896 
immunization  897 
Spleens and genital tracts were collected 2 days following intraperitoneal infusion of (A) 898 
αCD4, (B) αCD8 and (C) αCD20 and depletion was confirmed using flow cytometry. 899 
Depletion was compared against isotype control infused mice. (D) Serum was screened for 900 
the presence of MOMP-specific Ig in MOMP/IMX immunized mice by ELISA following 901 
αCD20 infusion. (E) MOMP-specific Ig in the serum collected from MOMP/IMX immunized 902 
donor mice (M/I Imm.) and serum from recipient naïve mice passively immunized with 903 
MOMP/IMX serum (Passive Imm.) were analyzed by ELISA. 904 
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S5: Protection against genital tract infection in male mice following immunization and 915 
challenged with C. muridarum.  916 
Male mice were challenged with 1x106 IFU C. muridarum and their prostatic fluid (PF), 917 
penis and testes were collected 7 days p.i (n = 5). The amount of Chlamydia presented in 918 
each sample (IFU/sample) was quantified by culture. Results are presented as the mean ± 919 
SEM. Significant levels of bacterial burden and disease severity were determined using a one 920 
-way ANOVA with Tukey’s post -test. Significance was set at p < 0.05 for all tests. p>0.05 921 
(not shown), 0.01-0.05 (*), 0.001- 0.01 (**) and <0.001 (***). 922 
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S6: Electro-stimulation schedule for collection of prostatic fluid 948 
 Frequency (Hz) Pulse width (ms) Intensity (V) Duration (min:sec) 
*1. 1.0 1.0 0.5 0:30 
2. 1.0 1.0 1.0 0:30 
3. 1.0 1.0 1.5 0:30 
4. 1.0 1.0 2.0 0:30 
5. 2.0 1.0 2.5 0:30 
6. 2.0 1.0 5.0 0:30 
#7. 2.0 1.0 7.5 0:30 
8. 2.0 1.0 10.0 0:30 
†9.  2.0 – 10.0 – 2.0 1.0 10.0 0:04 x 5 
10. 2.0 – 10.0 – 2.0 1.0 15.0 0:04 x 5 
11. 2.0 – 10.0 – 2.0 1.0 20.0 0:04 x 5 
   Total 5:00 
*Urine contamination can be produced early during the procedure and must be discarded. 949 
#Prostatic fluid is typical produced from this point onwards. †Frequency is increased for 1 950 
sec, held at maximum for 2 sec and decreased for 1 sec. This cycle is repeated five times for 951 
each intensity setting 952 
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S7: Primers for RT-PCR 977 
Gene Accession No. Forward Primer (5' to 3') Reverse Primer (5' to 3') 
CXCL1 NM_008176.3 ACCCAAACCGAAGTCATAGCC TTGTCAGAAGCCAGCGTTCA 
CXCL2 NM_009140.2 CCCAGACAGAAGTCATAGCCAC CGAGGCACATCAGGTACGAT 
CXCL5 NM_009141.3 GCCCCTTCCTCAGTCATAGC AGCTTTCTTTTTGTCACTGCCC 
IL-1β NM_008361.3 TGCCACCTTTTGACAGTGATG AAGGTCCACGGGAAAGACAC 
Caspase-1 NM_009807.2 TGAAAGAATTTGCTGCCTGCC CCTTGTTTCTCTCCACGGCAT 
IFNγ NM_008337.3 AGGAACTGGCAAAAGGATGGT TCATTGAATGCTTGGCGCTG 
IL-17A NM_010552.3 TGAGTCCAGGGAGAGCTTCA CATTGCGGTGGAGAGTCCAG 
IL-17F NM_145856.2 CGTGAAACAGCCATGGTCAAG GGGGGTCTCGAGTGATGTTG 
TNFα NM_013693.3 ACGTCGTAGCAAACCACCAA ATAGCAAATCGGCTGACGGT 
ActB NM_007393.3 AGAGGGAAATCGTGCGTGAC CAATCGTGATGACCTGGCCGT 
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